PCIDB

KNApSAcK Metabolite C00002868

Metabolite

KNApSAcK Entry

id C00002868
Name Vitamin K1 / Phylloquinone / Vitamin K1(20) / trans-Phylloquinone
CAS RN 84-80-0
Standard InChI InChI=1S/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+/t23-,24-/m1/s1
Standard InChI (Main Layer) InChI=1S/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,18-20,22-24H,9-17,21H2,1-6H3

Cluster

Phytochemical cluster
KCF-S cluster No. 6845

Link

ChEMBL

By standard InChI CHEMBL1550
By standard InChI Main Layer CHEMBL1550 CHEMBL520156 CHEMBL2024140

KEGG

By LinkDB C02059

CTD

By CAS RN D010837

Human Protein / Gene in interaction

10 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
O75469 Nuclear receptor subfamily 1 group I member 2 NR1I2 CHEMBL1550 CHEMBL2024140 CHEMBL1809501 (1) CHEMBL2025111 (1)
CHEMBL2025112 (1)
0 / 0
P11473 Vitamin D3 receptor NR1I1 CHEMBL520156 CHEMBL1794311 (1)
2 / 3
P14902 Indoleamine 2,3-dioxygenase 1 Enzyme CHEMBL1550 CHEMBL935410 (1)
0 / 0
Q92830 Histone acetyltransferase KAT2A Enzyme CHEMBL520156 CHEMBL1738606 (1)
0 / 0
O75496 Geminin Unclassified protein CHEMBL1550 CHEMBL520156 CHEMBL2114843 (2) CHEMBL2114780 (1)
0 / 0
Q9Y253 DNA polymerase eta Enzyme CHEMBL1550 CHEMBL1794569 (1)
1 / 1
P83916 Chromobox protein homolog 1 Unclassified protein CHEMBL520156 CHEMBL1794401 (1)
0 / 0
O94782 Ubiquitin carboxyl-terminal hydrolase 1 Enzyme CHEMBL520156 CHEMBL1794467 (1)
0 / 0
Q9UNA4 DNA polymerase iota Enzyme CHEMBL1550 CHEMBL520156 CHEMBL1794483 (2)
0 / 0
Q96KQ7 Histone-lysine N-methyltransferase EHMT2 Enzyme CHEMBL520156 CHEMBL1738442 (1)
0 / 0

CTD interaction (14)

compound gene gene name gene description interaction interaction type form reference
pmid
D010837 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [sorafenib co-treated with Vitamin K 1] results in decreased expression of BCL2 protein affects cotreatment
/ decreases expression
protein 20301194
D010837 637 BID
FP497
BH3 interacting domain death agonist [sorafenib co-treated with Vitamin K 1] results in increased cleavage of BID protein affects cotreatment
/ increases cleavage
protein 20301194
D010837 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [sorafenib co-treated with Vitamin K 1] results in increased cleavage of CASP3 protein affects cotreatment
/ increases cleavage
protein 20301194
D010837 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) [sorafenib co-treated with Vitamin K 1] results in increased cleavage of CASP8 protein affects cotreatment
/ increases cleavage
protein 20301194
D010837 8529 CYP4F2
CPF2
cytochrome P450, family 4, subfamily F, polypeptide 2 (EC:1.14.13.30) CYP4F2 gene polymorphism results in decreased metabolism of Vitamin K 1 decreases metabolic processing
gene 22417713
D010837 8529 CYP4F2
CPF2
cytochrome P450, family 4, subfamily F, polypeptide 2 (EC:1.14.13.30) CYP4F2 protein results in increased oxidation of Vitamin K 1 increases oxidation
protein 19297519
D010837 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) Vitamin K 1 deficiency results in increased expression of F2 protein modified form increases expression
protein 2821104
D010837 356 FASLG
ALPS1B
APT1LG1
APTL
CD178
CD95-L
CD95L
FASL
TNFSF6
Fas ligand (TNF superfamily, member 6) anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [[sorafenib co-treated with Vitamin K 1] results in increased expression of FASLG protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 20301194
D010837 356 FASLG
ALPS1B
APT1LG1
APTL
CD178
CD95-L
CD95L
FASL
TNFSF6
Fas ligand (TNF superfamily, member 6) [sorafenib co-treated with Vitamin K 1] results in increased expression of FASLG protein affects cotreatment
/ increases expression
protein 20301194
D010837 2353 FOS
AP-1
C-FOS
p55
FBJ murine osteosarcoma viral oncogene homolog Vitamin K 1 results in increased expression of FOS mRNA increases expression
mRNA 19273458
D010837 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [[sorafenib co-treated with Vitamin K 1] results in increased phosphorylation of JUN protein] affects cotreatment
/ decreases reaction
/ increases phosphorylation
protein 20301194
D010837 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene [sorafenib co-treated with Vitamin K 1] results in increased phosphorylation of JUN protein affects cotreatment
/ increases phosphorylation
protein 20301194
D010837 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) [sorafenib co-treated with Vitamin K 1] results in decreased phosphorylation of MAPK1 protein affects cotreatment
/ decreases phosphorylation
protein 20301194
D010837 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) [sorafenib co-treated with Vitamin K 1] results in decreased phosphorylation of MAPK3 protein affects cotreatment
/ decreases phosphorylation
protein 20301194

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (3)

OMIM preferred title UniProt
#607948 Mycobacterium tuberculosis, susceptibility to P11473
#277440 Vitamin d-dependent rickets, type 2a; vddr2a P11473
#278750 Xeroderma pigmentosum, variant type; xpv Q9Y253

KEGG DISEASE (4)

KEGG disease name UniProt
H00342 Tuberculosis P11473 (related)
H00784 Localized autosomal recessive hypotrichosis P11473 (related)
H01143 Vitamin D-dependent rickets P11473 (related)
H00403 Disorders of nucleotide excision repair Q9Y253 (related)

Diseases related to CTD interactions

7 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D002114 D010837 Calcinosis marker/mechanism
21193197
D002543 D010837 Cerebral Hemorrhage therapeutic
1723166
D003875 D010837 Drug Eruptions marker/mechanism
8936071
D004485 D010837 Eczema marker/mechanism
8936071
D006406 D010837 Hematoma therapeutic
1723166
D006973 D010837 Hypertension marker/mechanism
12172322
12559675
D012594 D010837 Scleroderma, Localized marker/mechanism
8936071